RE: The Daily Mail reported. Studies reportedly suggest the drug, leronlimab, calms the overly aggressive immune response that could lead to pneumonia and even death.
Well, Dr.William Grace said the same thing of hydroxychloroquine. It modulates the over reactive response of the body’s immune system to Covid-19.
The question is this -— which one does it better at a cheaper price? leronlimab, or hydroxychloroquine?
I have the impression that most of these biologics ending in "mab" run on the order of $3K per month and I suspect that there is limited production capacity. So hydroxychloroquine should be much more attractive in a pandemic, unless you are a Big Pharma company.
Question is, which is the more effective for most people? the lesser effective can be used when the primary fails... Remember, we are talking about medicine here folks, there is natural genetic diversity, even if something works on 99% of the people there will still be that 1% it will not... no matter what you do. Having more than one option is a good think...
Which ever is most effective is used first, when that fails, other options are tried.
The “nice” think about this, if you can say any nice, is that it is the suppression ion of the immune response that is allowing survival, not an antiviral or antibiotic, that the virus could mutate and become immune to.
If these drugs do help these patients, in the large scale, they can be used for other things that cause such reactions in people, nut just the Kung Flu.
This looks like one of those drugs where "if you have to ask, you can't afford it".
CytoDyn is expected to price leronlimab at a similar price to its main rival, Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics), which commands an exceptionally high annual list price of approximately $118,000 per patient.
I'm sure a larger patient pool would bring that down some and you might only need a fraction of the amount a cancer patient uses, but it isn't cheap...